Skip to main content
Premium Trial:

Request an Annual Quote

GE to Acquire Amersham in 5.7B Stock Deal: Amersham Life Science Business To Be Combined with GE Medical

NEW YORK, Oct. 10 (GenomeWeb News) -   General Electric has made a successful bid to acquire Amersham PLC in an £5.7 billion ($9.5 billion) all-stock deal, subject to the waiver of some "regulatory pre-conditions," the companies said early today.


Statements by GE executives indicate that the company plans to retain Amersham's life sciences business in the acquisition. GE Healthcare Technologies, to be based in the UK, will combine Amersham and GE Medical, the companies said.


"Amersham's diagnostic pharmaceutical and life sciences business will add new, high growth platforms to GE Medical's diagnostic imaging, services and healthcare information technology businesses," Jeffrey Immelt, chairman and CEO of GE said in a statement. "The combination of this technological and market knowledge will allow GE to accelerate the development of molecular imaging and personalised medicine where it will be possible to predict and treat disease with therapies tailored to the individual."


When the acquisition is complete, Sir William Castell, chairman of Amersham, will become a vice chairman of GE  as well as CEO of GE Healthcare Technologies, and will Join GE's board. However, Joseph Hogan, who is a senior vice president of GE and leader of GE Medical, will continue in this position, the companies said.


The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.